Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 6, 2010, Pages 892-897

  Fujiwara, Yuki ^a   Shiba, Hiroaki ^a   Furukawa, Kenei ^a   Iida, Tomonori ^a   Sakamoto, Taro ^a   Gocho, Takeshi ^a   Wakiyama, Shigeki ^a   Hirohara, Shoichi ^a   Ishida, Yuichi ^a   Misawa, Takeyuki ^a   Ohashi, Toya ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatectomy; Hepatocellular carcinoma; White blood cell count

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TRANSFUSION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; ELECTIVE SURGERY; HUMAN; IMMUNE RESPONSE; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; BLOOD; FOLLOW UP; INCIDENCE; JAPAN; LIVER TUMOR; METHODOLOGY; MORTALITY; NEOPLASM; TREATMENT OUTCOME; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INCIDENCE; JAPAN; LEUKOCYTE COUNT; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PERIOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952198651     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-010-0290-4     Document Type: Article

References (53)

1. EL-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-50. (Pubitemid 29114292)
2. Ercolani G, Grazi GL, Ravaioli M, Gaudio MD, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536-43. (Pubitemid 38176435)
3. Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, Oriyama T, Furukawa K, Kawamura E. Prognostic factors after hepatectomy for hapatocellular carcinomas. Cancer. 1990;65:1104-10.
4. Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993;113:612-8. (Pubitemid 23176302)
5. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63-70. (Pubitemid 32619336)
6. Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg. 1995;19:35-41.
7. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at Western center. Ann Surg. 1999;229:790-800. (Pubitemid 30191728)
8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17. (Pubitemid 37518510)
9. Takayama T, Makuuchi S, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with high rate of surgical care. Hepatology. 1998;28:1241-6. (Pubitemid 28493833)
10. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immune therapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356:802-7.
11. Chen MF, Hwang TL, Jeng LB, Jan YY, Wang CS, Chou FF. Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg. 1989;124:1025-8.
12. Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990;211:28-33. (Pubitemid 20027879)
13. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukawa H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993;105:488-94. (Pubitemid 23213535)
14. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114-7.
15. Yanaga K, Okudaira S, Kanematsu T, Marsh JW. Hepatic resection for hepatocellular carcinoma. In: Carr B, editor. Hepatocellular cancer: diagnosis and treatment. Totowa: Humana; 2005. p. 185-98.
16. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS Jr, Emond JC. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250:141-51.
17. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32:1757-62.
18. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 2008;139:755-64.
19. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol. 2000;15:431-6. (Pubitemid 30262212)
20. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol. 1999;31:323-31. (Pubitemid 29349760)
21. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000;95:2936-9.
22. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg. 1995;169:589-94.
23. Bureau of Medical Safety, Ministry of Health and Welfare. Guidelines for administering blood preparations. Medical and Pharmaceutical Notification No. 715, 10 June, 1999.
24. Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002;24:395-403. (Pubitemid 36002129)
25. Bruckner HW, Lavin PT, Plaxe SG, Storch JA, Livstone EM. Absolute granulocyte, lymphocyte, and monocyte counts; useful determinants of prognosis for patients with metastasis cancer of the stomach. JAMA. 1982;247:1004-6. (Pubitemid 12162304)
26. Elias EG, Leuchten JM, Buda BS, Brown SD. Prognostic value of initial mononucleated cell percentages in patients with epidermoid carcinoma of the head and neck. Am J Surg. 1986;152:487-90. (Pubitemid 17179145)
27. Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25:135-40.
28. Curiel T, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9. (Pubitemid 39273735)
29. + T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465-72.
30. + regulatory T cells in patients with hepatocellular carcinoma. EJSO. 2008;34:173-9.
31. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65:2457-64. (Pubitemid 40490158)
32. Unitt E, Rushbrook SM, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005;41:722-30. (Pubitemid 40462933)
33. + regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 2006;45:254-62.
34. Kono K, Kawaida H, Takahashi A, et al. CD4(+) CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55:1064-71. (Pubitemid 43800721)
35. Bueter M, Gasser M, Schramm N, et al. T-cell response to p53 tumor associated antigen in patients with colorectal carcinoma. Int J Oncol. 2006;28:431-8.
36. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-61. (Pubitemid 34921025)
37. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-34. (Pubitemid 44497257)
38. + T cells accumulate in lung adenocarcinoma. J Immunol. 2006;177:6983-90.
39. Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kumano H. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than normal tissues, especially in tumors smaller than 30 mm. Oncol Res. 2006;15:1315-9.
40. + CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-405.
41. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two type of murine helper T cell clones. Definition according to profiles of lymphokine activity and secreted proteins. J Immunol. 1986;136:2348-57. (Pubitemid 16136806)
42. Lan AK, Luk HN, Goto S, et al. Stress response to hepatectomy in patients with a healthy or diseased liver. World J Surg. 2003;27:761-4. (Pubitemid 37022384)
43. Rahman SH, Evans J, Toogood GJ, Lodge PA, Prasad KR. Prognostic utility of postoperative C-reactive protein for post-hepatectomy liver failure. Arch Surg. 2008;143:247-53. (Pubitemid 351439273)
44. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856-64. (Pubitemid 40563258)
45. Wong VK, Malik HZ, Hamady ZZ, et al. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer. 2007;96:222-5. (Pubitemid 46160625)
46. + T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology. 2000;120:512-24.
47. Moyes LH, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2009;100:1236-9.
48. Savill JS, Wyllie AH, Henson JE, et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Investig. 1989;83:865-75. (Pubitemid 19080618)
49. Kusaba N, Kumashiro R, Ogata H, et al. In vitro study of neutrophil apoptosis in liver cirrhosis. Intern Med. 1998;37:11-7.
50. Colotta F, Re F, Polentarutti N, Sozzani S, Montovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 1992;80:2012-20.
51. Brach MA, de Vos S, Gruss HJ, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte- macrophage colony-stimulating factor is caused by inhibition programmed death. Blood. 1992;80:2920-4.
52. Salamore G, Giordano M, Trevani AS, et al. Promotion of neutrophil apoptosis by TNF-alpha. J Immunol. 2001;166:3476-83.
53. Akgul C, Moulding DA, Edwards SW. Molecular control of neutrophil apoptosis. FEBS Lett. 2001;487:318-22. (Pubitemid 32121749)